| 1. |
- Beaussant, Y, et al.
(författare)
-
Hospital end-of-life care in haematological malignancies
- 2018
-
Ingår i: BMJ supportive & palliative care. - : BMJ. - 2045-4368 .- 2045-435X. ; 8:3, s. 314-324
-
Tidskriftsartikel (refereegranskat)abstract
- To investigate patterns of care during the last months of life of hospitalised patients who died from different haematological malignancies.MethodsNationwide register-based study, including all hospitalised adults ≥20 years who died from haematological malignancies in France in 2010–2013. Outcomes included use of invasive cancer treatments and referral to palliative care. Percentages are adjusted for sex and age using direct standardisation.ResultsOf 46 629 inpatients who died with haematological malignancies, 24.5% received chemotherapy during the last month before death, 48.5% received blood transfusion, 12.3% were under invasive ventilation and 18.1% died in intensive care units. We found important variations between haematological malignancies. The use of chemotherapy during the last month of life varied from 8.6% among patients with chronic myeloid leukaemia up to 30.1% among those with non-Hodgkin’s lymphoma (P<0.001). Invasive ventilation was used in 10.2% of patients with acute leukaemia but in 19.0% of patients with Hodgkin’s lymphoma (P<0.001). Palliative status was reported 30 days before death in only 14.8% of patients, and at time of death in 46.9% of cases. Overall, 5.5% of haematology patients died in palliative care units.ConclusionA high proportion of patients who died from haematological malignancies receive specific treatments near the end of life. There is a need for a better and earlier integration of the palliative care approach in the standard practice of haematology. However, substantial variation according to the type of haematological malignancy suggests that the patients should not be considered as one homogeneous group. Implementation of palliative care should account for differences across haematological malignancies.
|
|
| 2. |
|
|
| 3. |
- Rochigneux, P., et al.
(författare)
-
Use of chemotherapy near the end of life : what factors matter?
- 2017
-
Ingår i: Annals of Oncology. - : Elsevier BV. - 0923-7534 .- 1569-8041. ; 28:4, s. 809-817
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Use of chemotherapy near the end of life in patients with metastatic cancer is often ineffective and toxic. Data about the factors associated with its use remain scarce, especially in Europe. Methods: Nationwide, register-based study including all hospitalized patients aged >= 20 years who died from metastatic solid tumors in France between 2010 and 2013. Results: A total of 279 846 hospitalized patients who died from metastatic cancer were included. During the last month before death, 19.5% received chemotherapy (including 11.3% during the last 2 weeks). Female sex (OR = 0.96, 95% CI = 0.93-0.98), older age (OR = 0.70, 95% CI = 0.69-0.71 for each 10-year increase) and higher number of chronic comorbidities (OR = 0.83, 95% CI = 0.82-0.84) were independently associated with lower rates of chemotherapy. Although patients with chemosensitive tumors were statistically more likely to receive chemotherapy during the last month before death (OR = 1.21, 1.18-1.25), this association was mostly fueled by testis and ovary tumors and we found no obvious pattern between the expected chemosensitivity of different cancers and the rates of chemotherapy use close to death. Compared with university hospitals, patients who died in for-profit clinics/hospital (OR = 1.40, 95% CI = 1.34-1.45), or comprehensive cancer centers (OR = 1.43, 95% CI = 1.36-1.50) were more likely to receive chemotherapy. Finally, high-volume centers and hospitals without palliative care units reported greater-than-average rates of chemotherapy near the end of life. Conclusion: among hospitalized patients with cancer, young individuals, treated in comprehensive cancer centers or in high-volume centers without palliative care units were the most likely to receive chemotherapy near the end of life. We found no evident pattern between the expected chemosensitivity of different cancers and the probability for patients to receive chemotherapy close to death.
|
|
| 4. |
- Serezal, I. Gallais, et al.
(författare)
-
End-of-life care for hospitalized patients with metastatic melanoma in France : a nationwide, register-based study
- 2016
-
Ingår i: British Journal of Dermatology. - : Oxford University Press (OUP). - 0007-0963 .- 1365-2133. ; 175:3, s. 583-592
-
Tidskriftsartikel (refereegranskat)abstract
- BackgroundAlthough the aggressiveness of end-of-life cancer care has come under great scrutiny over the past two decades, little is known about the intensity of care and treatments in the last months of life of patients with metastatic melanoma. ObjectivesTo measure the prevalence of aggressive cancer care use, and to assess the frequency of palliative care referral over the course of the last 3 months of life of hospitalized patients who died from metastatic melanoma. MethodsA nationwide register-based study in France was carried out, including all hospitalized adults aged 20 years who died from metastatic melanoma in metropolitan France between 2010 and 2013. ResultsOf 3889 patients who died from metastatic melanoma, 519% received chemotherapy in the last 3 months before death, 259% in the last month, 129% in the last 2 weeks and 76% in the last week. On average, patients were hospitalized for 317 days over the course of their last 3 months of life. During the final month before death, 120% of patients received radiation therapy, 140% received blood transfusion, 121% were transferred into an intensive care unit and 197% remained hospitalized continuously. Palliative care needs were identified in 784% of patients, with variations according to the type of facility. In total 17% of all patients died in palliative care inpatient units. ConclusionsTreatment intensity near the end of life of patients with metastatic melanoma raises concerns for the quality of care. There is a need for clinical guidelines and adequate support to facilitate patient-physician communication and to improve access to palliative care services.
|
|
